What are the key clinical trials and their expected timelines for VKTX?

Viking Therapeutics (VKTX) has several key clinical trials underway or planned, including:

1. **Phase 3 VANQUISH Trial for VK2735**: Initiated in Q2 2025, this trial is evaluating the efficacy and safety of VK2735 in approximately 5,600 patients with obesity and type 2 diabetes. Expected timeline: completion in 2026.
2. **Phase 2 VENTURE-Oral Dosing Trial for VK2735**: Completed enrollment in Q1 2024, with results expected later in 2024. This trial evaluated the safety and efficacy of oral VK2735 in patients with obesity.
3. **Phase 2 Trial for VK2809**: This trial is evaluating the efficacy and safety of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. Expected timeline: completion in 2025.
4. **Phase 1 Trial for VK0214**: This trial is assessing the safety and efficacy of VK0214 in patients with X-linked adrenoleukodystrophy (X-ALD). Expected timeline: ongoing.

These clinical trials are pivotal for VKTX's development pipeline and the company's future revenue generation. The successful completion of these trials could lead to regulatory approvals and significant revenue streams. However, delays or adverse outcomes in these trials could have substantial impacts on the company's financials and investor sentiment.